Anixa Biosciences (ANIX) CEO purchases 3,188 shares at $3.37 each

Rhea-AI Filing Summary

Anixa Biosciences Inc reported that Chief Executive Officer Amit Kumar purchased 3,188 shares of Common Stock on July 27, 2026, at $3.37 per share in a purchase in open market or private transaction. Following this transaction, he directly holds 647,000 shares.

Insider Trade Summary

Net Buyer: 3,188 shares

Net Buy 1 txn

Insider KUMAR AMIT

Role Chief Executive Officer

Bought 3,188 shs ($11K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	3,188	$3.37	$11K

Holdings After Transaction: Common Stock — 647,000 shares (Direct)

Key Figures

Shares purchased: 3,188 shares Purchase price: $3.37 per share Holdings after transaction: 647,000 shares +1 more

4 metrics

Shares purchased 3,188 shares Common Stock transaction on July 27, 2026

Purchase price $3.37 per share Price for Common Stock purchased by CEO Amit Kumar

Holdings after transaction 647,000 shares Direct Common Stock ownership following the purchase

Net shares bought 3,188 shares Net-buy direction across reported insider transactions

Key Terms

Purchase in open market or private transaction

1 terms

Purchase in open market or private transaction financial

"transaction_code_description: Purchase in open market or private transaction"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/27/2026 - 03:25 PM Accepted by SEC EDGAR 07/27/2026 - 03:25 PM Learn about SEC filing dates

FAQ

What insider share purchase did Anixa Biosciences (ANIX) report?

Chief Executive Officer Amit Kumar bought 3,188 Anixa Biosciences Common Stock shares at $3.37 each on July 27, 2026. After this open-market or private purchase, his directly held stake increased to 647,000 shares, based on the reported insider ownership information.

At what price did the ANIX CEO acquire new shares?

Amit Kumar acquired 3,188 Anixa Biosciences shares at a price of $3.37 per share. The transaction is classified as a purchase in an open market or private transaction, reflecting a direct increase in his Common Stock holdings.

How many Anixa Biosciences (ANIX) shares does the CEO own after the trade?

Following the reported transaction, CEO Amit Kumar directly owns 647,000 Anixa Biosciences Common Stock shares. This figure includes the newly purchased 3,188 shares from July 27, 2026, and represents his post-transaction direct ownership position.

Was the recent ANIX insider activity a buy or a sell?

The reported insider activity for Anixa Biosciences (ANIX) was a buy transaction. CEO Amit Kumar purchased 3,188 Common Stock shares, with no shares reported sold in this disclosure, resulting in a net-buy direction for his holdings.

Was the ANIX CEO’s share purchase under a Rule 10b5-1 trading plan?

The CEO’s reported share purchase is not indicated as executed under a Rule 10b5-1 trading plan. The plan-status field for this insider transaction is marked false, suggesting it was not carried out pursuant to an affirmed trading plan election.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KUMAR AMIT

(Last) (First) (Middle)

C/O ANIXA BIOSCIENCES, INC.

3150 ALMADEN EXPRESSWAY, SUITE 250

(Street)

SAN JOSE, CALIFORNIA 95118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Anixa Biosciences Inc [ ANIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/27/2026		P		3,188	A	$3.37	647,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Amit Kumar	07/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)